Phase 2 Trials

Sanofi to Acquire Vigil Neuroscience in $600M Deal to Advance Alzheimer’s Research

The acquisition includes VG-3927, a Phase 2-ready TREM2 agonist, with a focus on microglial neuroprotection in Alzheimer’s disease.